デフォルト表紙
市場調査レポート
商品コード
925377

癌免疫アッセイ市場:成長、動向、予測(2022~2027)

Immuno Oncology Assays Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 100 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=137.14円
癌免疫アッセイ市場:成長、動向、予測(2022~2027)
出版日: 2022年01月17日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 100 Pages
納期: 2~3営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

癌免疫アッセイ市場は、予測期間にわたってほぼ12.3%のCAGRで成長すると予測されました。市場の成長に起因する主な要因は、がんの発生率の増加です。世界保健機関(WHO)によると、 世界のがんの発生は2018年には新しく1810万件数に上昇し、960万人が死亡すると予想されています。世界中の男性の5人に1人、女性の6人に1人が人生の中で癌になり、男性の8人に1人、女性の11人に1人が癌でなくなっています。さらに、標的療法の採用の増加は市場の成長を後押ししています。

当レポートでは、癌疫学アッセイ市場を調査し、市場概要、市場の成長要因および阻害要因の分析、製品別・技術別・徴候別・地域別の市場規模の推移と予測、競合情勢、主要企業のプロファイル、市場機会など、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 市場成長要因
    • 世界的に癌の発生率の上昇
    • 標的療法の採用の増加
  • 市場の抑制要因
    • 不利な規制および償還シナリオ
  • ポーターのファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 競争の激化

第5章 市場細分化

  • 製品別
    • 試薬と抗体
    • 楽器
    • ソフトウェア
    • 消耗品とアクセサリー
  • テクノロジー別
    • イムノアッセイ
    • PCR
    • NGS
    • フローサイトメトリー
    • その他の技術
  • 徴候別
    • 肺癌
    • 大腸がん
    • 黒色腫
    • その他のがん
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ地域
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Agilent Technologies, Inc
    • Thermo Fisher Scientific
    • Illumina, Inc.
    • PerkinElmer, Inc.
    • Crown Bioscience Inc.
    • InSphero.
    • Merck & Company, Inc.
    • F. Hoffmann-La Roche Ltd.
    • HTG Molecular Diagnostics, Inc.

第7章 市場機会および将来動向

目次
Product Code: 67959

The Immuno Oncology Assays market studied was projected to grow with a CAGR of nearly 12.3% over the forecast period. The major factor attributing to the growth of the market is the increase in the incidence of cancer. According to the World Health Organization, the global cancer burden is expected to have risen to 18.1 million new cases and 9.6 million deaths in 2018. One in 5 men and one in 6 women worldwide developed cancer during their lifetime, and one in 8 men and one in 11 women die from the disease. Furthermore, increasing adoption of targeted therapy is boosting the market growth. Immuno oncology assays are used to measure the concentration of the therapeutic antibody, anti-drug antibodies and soluble protein biomarkers. As the popularity of targeted therapy increases the market growth of the assays increase. However, stringent and unfavorable refund policies is the major drawback of market growth.

Key Market Trends

Reagents and Antibodies Segment is Dominating the Immuno Oncology Assays Market.

Reagents and antibodies segment has the maximum share in the market due to factors like increasing demand for the products. The demand is directly proportional to the increasing incidence of several types of cancer globally. As previously stated the global burden of cancer has risen to 18.1 million new cases in the year 2018 as reported by the World Health Organization. The increasing cancer load is due to numerous factors, including population growth and aging as well as the changing frequency of certain causes of cancer linked to social and economic development. Cancers of the lung and female breast are the top categories worldwide in terms of the number of new cases, for each of these types, approximately 2.1 million diagnoses are estimated in 2018, contributing about 11.6% of the total cancer incidence burden. As the cancer diagnosis is increasing the need for the reagent and antibodies increases, thus propelling the segment growth.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to factors such as the presence of key players, the high prevalence of cancer in the region, established healthcare infrastructure are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase the market growth. In this region the United States has the maximum share due to supportive healthcare policies, the high number of patients, and a developed healthcare market. According to the National Institutes of Health (NIH), in 2018, an estimated 1,735,350 new cases of cancer will be detected in the United States and 609,640 people will die from the disease. The statistics prove that the prevalence of cancer is high in the country and this boosts the market growth.

Competitive Landscape

The Immuno Oncology Assays market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Agilent Technologies, Inc, Thermo Fisher Scientific, Cisbio, Illumina, Inc., PerkinElmer, Inc., Crown Bioscience Inc., InSphero., Merck & Company, Inc., F. Hoffmann-La Roche Ltd., HTG Molecular Diagnostics, Inc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Incidence of Cancer Globally
    • 4.2.2 Increasing Adoption of Targeted Therapy
  • 4.3 Market Restraints
    • 4.3.1 Unfavorable Regulatory and Reimbursement Scenario
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Reagents and Antibodies
    • 5.1.2 Instruments
    • 5.1.3 Software
    • 5.1.4 Consumables and Accessories
  • 5.2 By Technology
    • 5.2.1 Immunoassay
    • 5.2.2 PCR
    • 5.2.3 NGS
    • 5.2.4 Flow Cytometry
    • 5.2.5 Other Technologies
  • 5.3 By Indication
    • 5.3.1 Lung Cancer
    • 5.3.2 Colorectal Cancer
    • 5.3.3 Melanoma
    • 5.3.4 Other Cancers
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Agilent Technologies, Inc
    • 6.1.2 Thermo Fisher Scientific
    • 6.1.3 Illumina, Inc.
    • 6.1.4 PerkinElmer, Inc.
    • 6.1.5 Crown Bioscience Inc.
    • 6.1.6 InSphero.
    • 6.1.7 Merck & Company, Inc.
    • 6.1.8 F. Hoffmann-La Roche Ltd.
    • 6.1.9 HTG Molecular Diagnostics, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS